CAFs and DCs are also known to exploit TGF-β signals to deploy pro-tumorigenic actions by releasing several molecules that, in aggregate, attract Tregs to tumor sites to compromise CTL immune responses [283]. Here, TGFB1 is linked to neoplasm.